Heterocyclic amides as kinase inhibitors

1. A compound according to Formula (I):

wherein:

X is O;

Y is CH 2 or CH 2 CH 2 ;

Z 1 is N, CH or CR 1 ;

Z 2 is CH or CR 2 ;

Z 3 is N, CH or CR 3 ;

Z 4 is CH or CR 4 ;

R 1 is fluoro or methyl;

one of R 2 and R 3 is halogen, cyano, (C 1 -C 6 )alkyl, halo(C 1 -C 4 )alkyl, (C 1 -C 6 )alkoxy, halo(C 1 -C 4 )alkoxy, hydroxyl, B(OH) 2 , —COOH, halo(C 1 -C 4 )alkylC(OH) 2 —, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkoxy, (C 1 -C 4 )alkylSO 2 —, (C 1 -C 4 )alkylSO 2 NHC(O)—, (C 1 -C 4 )alkylC(O)NH—, ((C 1 -C 4 )alkyl)((C 1 -C 4 )alkyl)NC(O)—, (C 1 -C 4 )alkylOC(O)—, (C 1 -C 4 )alkylC(O)N(C 1 -C 4 )alkyl)-, (C 1 -C 4 )alkylNHC(O)—, (C 1 -C 4 )alkoxy(C 2 -C 4 )alkylNHC(O)—, (C 1 -C 4 )alkoxy(C 2 -C 4 )alkylNHC(O)NH—, (C 1 -C 4 )alkylSO 2 (C 2 -C 4 )alkylNHC(O)—,(C 1 -C 4 )alkylNHC(O)NH—, (C 1 -C 4 )alkylOC(O)NH—, hydroxy(C 1 -C 4 )alkylOC(O)NH—, 5-6 membered heterocycloalkyl-C(O)—, 5-6 membered heterocycloalkyl-(C 1 -C 4 )alkyl-NHC(O)—, 5-6 membered heterocycloalkyl-(C 1 -C 4 )alkoxy-, 3-6 membered cycloalkyl, 5-6 membered heteroaryl, or 5-6 membered heteroaryl-C(O)NH,

wherein said 3-6 membered cycloalkyl, 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl are optionally substituted by 1 or 2 substituents each independently selected from the group consisting of (C 1 -C 4 )alkyl and —(C 1 -C 4 )alkyl-CN;

and the other of R 2 and R 3 is halogen, cyano or (C 1 -C 6 )alkyl;

R 4 is fluoro, chloro, methyl trifluoromethyl;

R 5 is H or methyl,

A is phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocycloalkyl, wherein the carbonyl moiety and L are substituted 1,3 on ring A;

m is 0 or m is 1 and R A is (C 1 -C 4 )alkyl; and

L is O, S, NH, N(CH 3 ), CH 2 , CH 2 CH 2 , CH(CH 3 ), CHF, CF 2 , CH 2 O, CH 2 N(CH 3 ), CH 2 NH, or CH(OH);

B is an optionally substituted (C 1 -C 6 )cycloalkyl, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocycloalkyl;

wherein said (C 3 -C 6 )cycloalkyl, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocycloalkyl is unsubstituted or is substituted by one or two substituents each independently selected from halogen, (C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, halo(C 1 -C 4 )alkoxy, nitro, and (C 1 -C 4 )alkylC(O)—;

or the moiety -L-B is (C 3 -C 6 )alkyl, (C 3 -C 6 )alkoxy, halo(C 3 -C 6 )alkoxy, (C 3 -C 6 )alkenyl, or (C 3 -C 6 )alkenyloxy;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , or pharmaceutically acceptable salt thereof, wherein:

X is O;

Y is CH 2 or CH 2 CH 2 ;

Z 1 is N, CH or CR 1 ;

Z 2 is CH or CR 2 ;

Z 3 is N, CH or CR 3 ;

Z 4 is CH or CR 4 ;

R 1 is fluoro or methyl;

one of R 2 and R 3 is halogen, cyano, (C 1 -C 6 )alkyl, halo(C 1 -C 4 )alkyl, (C 1 -C 6 )alkoxy, halo(C 1 -C 4 )alkoxy, hydroxyl, B(OH) 2 , —COOH, halo(C 1 -C 4 )alkylC(OH) 2 —, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkoxy, (C 1 -C 4 )alkylSO 2 —, (C 1 -C 4 )alkylSO 2 NHC(O)—, (C 1 -C 4 )alkylC(O)NH—, ((C 1 -C 4 )alkyl)((C 1 -C 4 )alkyl)NC(O)—, (C 1 -C 4 )alkylOC(O)—, (C 1 -C 4 )alkylC(O)N(C 1 -C 4 )alkyl)-, (C 1 -C 4 )alkylNHC(O)—, (C 1 -C 4 )alkoxy(C 2 -C 4 )alkylNHC(O)—, (C 1 -C 4 )alkoxy(C 2 -C 4 )alkylNHC(O)NH—, (C 1 -C 4 )alkylSO 2 (C 2 -C 4 )alkylNHC(O)—,(C 1 -C 4 )alkylNHC(O)NH—, (C 1 -C 4 )alkylOC(O)NH—, hydroxy(C 1 -C 4 )alkylOC(O)NH—, 5-6 membered heterocycloalkyl-C(O)—, 5-6 membered heterocycloalkyl-(C 1 -C 4 )alkyl-NHC(O)—, 5-6 membered heterocycloalkyl-(C 1 -C 4 )alkoxy-, 3-6 membered cycloalkyl, 5-6 membered heteroaryl, or 5-6 membered heteroaryl-C(O)NH,

wherein said 3-6 membered cycloalkyl, 5-6 membered heterocycloalkyl and 5-6 membered heteroaryl are optionally substituted by 1 or 2 substituents each independently selected from the group consisting of (C 1 -C 4 )alkyl and —(C 1 -C 4 )alkyl-CN;

and the other of R 2 and R 3 is halogen or (C 1 -C 6 )alkyl;

R 4 is fluoro, chloro, or methyl;

R 5 is H or methyl,

A is phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocycloalkyl, wherein the carbonyl moiety and L are substituted 1,3 on ring A;

m is 0 or m is 1 and R A is (C 1 -C 4 )alkyl; and

L is O, S, NH, N(CH 3 ), CH 2 , CH 2 CH 2 , CH(CH 3 ), CHF, CF 2 , CH 2 O, CH 2 N(CH 3 ), CH 2 NH, or CH(OH);

B is an optionally substituted (C 1 -C 6 )cycloalkyl, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocycloalkyl;

wherein said (C 3 -C 6 )cycloalkyl, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocycloalkyl is unsubstituted or is substituted by one or two substituents each independently selected from halogen, (C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, halo(C 1 -C 4 )alkoxy, nitro, and (C 1 -C 4 )alkylC(O)—;

or the moiety -L-B is (C 3 -C 6 )alkyl, (C 3 -C 6 )alkoxy, halo(C 3 -C 6 )alkoxy, (C 3 -C 6 )alkenyl, or (C 3 -C 6 )alkenyloxy.

3. the compound according to claim 1 , or pharmaceutically acceptable salt thereof, wherein:

X is O;

Y is CH 2 or CH 2 CH 2 ;

Z 1 is N, CH or CR 1 ;

Z 2 is CH or CR 2 ;

Z 3 is N, CH or CR 3 ;

Z 4 is CH or CR 4 ;

R 1 is fluoro or methyl;

one of R 2 and R 3 is halogen, cyano, (C 1 -C 6 )alkyl, halo(C 1 -C 4 )alkyl, (C 1 -C 6 )alkoxy, hydroxyl, B(OH) 2 , —COOH, halo(C 1 -C 4 )alkylC(OH) 2 —, (C 1 -C 4 )alkoxy(C 1 -C 4 )alkoxy, (C 1 -C 4 )alkylSO 2 —, (C 1 -C 4 )alkylSO 2 NHC(O)—, (C 1 -C 4 )alkylC(O)NH—, ((C 1 -C 4 )alkyl)((C 1 -C 4 )alkyl)NC(O)—, (C 1 -C 4 )alkylOC(O)—, (C 1 -C 4 )alkylC(O)N(C 1 -C 4 )alkyl)-, (C 1 -C 4 )alkylNHC(O)—, (C 1 -C 4 )alkoxy(C 2 -C 4 )alkylNHC(O)—, (C 1 -C 4 )alkoxy(C 2 -C 4 )alkylNHC(O)NH—, (C 1 -C 4 )alkylSO 2 (C 2 -C 4 )alkylNHC(O)—,(C 1 -C 4 )alkylNHC(O)NH—, (C 1 -C 4 )alkylOC(O)NH—, hydroxy(C 1 -C 4 )alkylOC(O)NH—, 5-6 membered heterocycloalkyl-C(O)—, 5-6 membered heterocycloalkyl-(C 1 -C 4 )alkyl-NHC(O)—, 5-6 membered heterocycloalkyl-(C 1 -C 4 )alkoxy-, 3-6 membered cycloalkyl, 5-6 membered heteroaryl, or 5-6 membered heteroaryl-C(O)NH,

wherein said 3-6 membered cycloalkyl, 5-6 membered heteroaryl are optionally substituted by 1 or 2 substituents each independently selected from the group consisting of (C 1 -C 4 )alkyl and —(C 1 -C 4 )alkyl-CN;

and the other of R 2 and R 3 is halogen or (C 1 -C 6 )alkyl;

R 4 is fluoro, chloro, or methyl;

R 5 is H or methyl,

A is phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocycloalkyl, wherein the carbonyl moiety and L are substituted 1,3 on ring A;

m is 0 or m is 1 and R A is (C 1 -C 4 )alkyl; and

L is O, S, NH, N(CH 3 ), CH 2 , CH 2 CH 2 , CH(CH 3 ), CHF, CF 2 , CH 2 O, CH 2 N(CH 3 ), CH 2 NH, or CH(OH);

B is an optionally substituted (C 1 -C 6 )cycloalkyl, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocycloalkyl;

wherein said (C 3 -C 6 )cycloalkyl, phenyl, 5-6 membered heteroaryl, or 5-6 membered heterocycloalkyl is unsubstituted or is substituted by one or two substituents each independently selected from halogen, (C 1 -C 4 )alkyl, halo(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, halo(C 1 -C 4 )alkoxy, nitro, and (C 1 -C 4 )alkylC(O)—;

or the moiety -L-B is (C 3 -C 6 )alkyl, (C 3 -C 6 )alkoxy, halo(C 3 -C 6 )alkoxy, (C 3 -C 6 )alkenyl, or (C 3 -C 6 )alkenyloxy.

4. The compound according to claim 2 , or pharmaceutically acceptable salt thereof, wherein:

X is O

Y is CH 2 or CH 2 CH 2 ,

Z 1 , Z 2 , Z 3 , and Z 4 are each CH; or

Z 1 is CR 1 and Z 2 , Z 3 and Z 4 are each CH; or

Z 1 , Z 2 , and Z 4 are each CH and Z 3 is CR 3 ; or

Z 1 , Z 3 , and Z 4 are each CH and Z 2 is CR 2 , or

Z 1 , Z 2 , and Z 3 are each CH and Z 4 is CR 4 ; or

Z 1 and Z 3 are CH, Z 2 is CR 2 , and Z 4 is CR 4 ;

or Z 1 and Z 3 are both N, Z 2 is CH and Z 4 is CH or CR 4 ; or

Z 1 is N, Z 2 is CR 2 and Z 3 and Z 4 are CH; or

Z 3 is N, and Z 2 , Z 3 and Z 4 are CH;

R 1 is methyl,

R 2 is chloro, bromo, —CN, —CH 3 , OH, B(OH) 2 , CF 3 C(OH) 2 , CH 3 OCH 2 CH 2 O—, 5H-tetrazol-5-yl, pyrazol-3-yl, or 5-methyl-1,3,4-oxadiazol-2-yl;

R 3 is fluoro, chloro, bromo, —OCH 3 , B(OH) 2 , —COOH, CH 3 SO 2 —, CH 3 SO 2 NHC(O)—, CH 3 C(O)NH—, (CH 3 ) 2 NC(O)—, CH 3 OC(O)—, (CH 3 )C(O)N(CH 3 )—, HOCH 2 CH 2 C(O)NH—, CH 3 OCH 2 CH 2 NHC(O)NH—, CH 3 SO 2 CH 2 CH 2 NHC(O)—, CH 3 CH 2 NHC(O)NH—, CH 3 OC(O)NH—, morpholin-4-yl-CO—, pyrrolidin-1-yl-CH 2 CH 2 NHC(O)—, tetrahydrofuran-2-yl-CH 2 O—, pyrrolidin-1-yl-CH 2 CH 2 O—, tetrazol-5-yl, 1-(2-cyanoethyl)-tetrazol-5-yl, pyrazol-1-yl, pyrazol-3-yl, 1-methyl-pyrazol-3-yl, 1-methyl-pyrrol-4-yl-C(O)NH—, or 5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl;

R 4 is fluoro or methyl;

A is furyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, 1 2,4-oxadiazolyl, 1,3,4-oxadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, piperidinyl, pyrrolidinyl, phenyl or pyridyl;

m is 0 or m is 1 and R A is methyl;

L is O, S, N(CH 3 ), CH 2 , CH 2 CH 2 , CH(CH 3 ), CF 2 , CH 2 O, CH 2 N(CH 3 ), or CH(OH); and

B is thien-2-yl, pyrazol-1-yl, 3,5-dimethylpyrazol-1-yl, 4-methylpyrazol-1-yl, 3,5-dimethylisoxazol-4-yl, tetrahydrofuran-2-yl, morpholin-4-yl, pyridin-2-yl, 2-oxo-pyridin-1-yl, 6-methylpyridin-3-yl, 2-methylpyrimidin-5-yl, cyclopentyl, cyclohexyl, phenyl, 2-methylphenyl, 4-methylphenyl, 2-trifluoromethylphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2-iodophenyl, 3-bromophenyl, 4-bromophenyl, 4-chlorophenyl, 2,5-difluorophenyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, or 4-methoxyphenyl;

or -L-B is OCH 2 CH═CH 2 , —CH 2 CH 2 CH 2 CH 2 CH 3 , —OCH 2 CH 2 CH 2 CH 3 , —CH 2 CH 2 CH 3 , or —CH 2 CH(CH 3 ) 2 .

5. The compound according to claim 1 , or pharmaceutically acceptable salt thereof, wherein Y is CH 2 .

6. The compound according to claim 2 , or pharmaceutically acceptable salt thereof, wherein Y is CH 2 .

7. The compound according to claim 4 , or pharmaceutically acceptable salt thereof, wherein Y is CH 2 .

8. A pharmaceutical composition comprising the compound according to claim 1 , or pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

9. A pharmaceutical composition comprising the compound according to claim 2 , or pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

10. A method of treating a RIP1 kinase mediated disease or disorder comprising administering a therapeutically effective amount of the compound or pharmaceutically acceptable salt thereof, according to claim 1 to a human in need thereof,

wherein the disease or disorder is selected from ulcerative colitis, Crohn's disease,

rheumatoid arthritis, psoriasis, spondyloarthritis, systemic onset juvenile idiopathic arthritis, psoriatic arthritis, osteoarthritis, multiple sclerosis, sepsis, ischemia reperfusion injury of solid organs, and systemic inflammatory response syndrome.